From Contrave Saga, Renewed Faith in Trials Built on Trust
September 19, 2015
Evidence-Based Diabetes Management
The decision by Cleveland Clinic's Steven Nissen, MD, to issue his own press release last spring after the cardiovascular outcomes trial was halted for Contrave turned plenty of heads in the pharmaceutical community. But Nissen and others involved in the saga see what happened with Orexigen as a one-time incident, not a flaw with the process for evaluating the safety of diabetes and obesity therapies.